# A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

> clinical trial · VERIFIED · 2026-06-12

Status: RECRUITING · Sponsor: Merck Sharp & Dohme LLC · Condition: Chronic Lymphocytic Leukemia

- Company: Merck Sharp & Dohme LLC
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT06136559

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED.